ArticleCancer medicine2020

How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA).

Massimo Breccia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.